Meta-substituted piperlongumine derivatives attenuate inflammation in both RAW264.7 macrophages and a mouse model of colitis.

Bioorg Chem

School of Pharmaceutical Sciences, Liaocheng University, 1 Hunan Street, Liaocheng, Shandong 252059, China. Electronic address:

Published: December 2021

Piperlongumine (PL) has been showed to have multiple pharmacological activities. In this study, we reported the synthesis of three series of PL derivatives, and evaluation of their anti-inflammatory effects in both lipopolysaccharide (LPS)-induced Raw264.7 macrophages and a dextran sulfate sodium (DSS)-induced mouse model of colitis. Our results presented that two meta-substituent containing derivatives 1-3 and 1-6, in which γ-butyrolactam replaced α,β-unsaturated δ-valerolactam ring of PL, displayed low cytotoxicity and effective anti-inflammatory activity. Molecular docking also showed that the meta-substituted derivative, compared with the corresponding ortho- or para-substituted derivative, had significant interactions with the amino acid residues of CD14, which was the core receptors recognizing LPS. In vitro and in vivo studies, 1-3 and 1-6 could inhibit the expression of pro-inflammatory cytokines, and the excessive production of reactive nitrogen species and reactive oxygen species. Oral administration of 100 mg/kg/day of 1-3 or 1-6 alleviated the severity of clinical symptoms of colitis in mice, and significantly reduced the colonic tissue damage to protect the colonic tissue from the DSS-induced colitis. These results suggested that meta-substituted derivatives 1-3 and 1-6 were potential anti-inflammatory agents, which may lead to future pharmaceutical development.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bioorg.2021.105465DOI Listing

Publication Analysis

Top Keywords

1-3 1-6
16
raw2647 macrophages
8
mouse model
8
model colitis
8
derivatives 1-3
8
colonic tissue
8
meta-substituted piperlongumine
4
derivatives
4
piperlongumine derivatives
4
derivatives attenuate
4

Similar Publications

Objectives: We aimed to estimate the prevalence of chronic bronchitis (CB), examine its association with occupational exposure to irritants assessed by self-reporting or the Nordic job exposure matrix (N-JEM) stratified by smoking status and estimate the population-attributable fraction (PAF) of CB from occupational exposure.

Methods: A two-phased, cross-sectional design was used to analyse a random sample collected in 2013 and 2018 of the population aged 16-55 years in Telemark County, Norway. CB was defined as cough and sputum production for ≥3 months over 2 consecutive years.

View Article and Find Full Text PDF

Objective: This study aimed to investigate patients' perceptions of nurse caring behaviours and their determinant factors at Debre Tabor Comprehensive Specialised Hospital (DTCSH) in Debre Tabor city, Ethiopia.

Design: A facility-based cross-sectional study was conducted among 474 patients admitted to the inpatient ward.

Setting: The study was conducted at DTCSH in Debre Tabor city.

View Article and Find Full Text PDF

Importance: Sexual dysfunction is a common adverse effect of prostate cancer treatment, and current management strategies do not adequately address physical and psychological causes. Exercise is a potential therapy in the management of sexual dysfunction.

Objective: To investigate the effects of supervised, clinic-based, resistance and aerobic exercise with and without a brief psychosexual education and self-management intervention (PESM) on sexual function in men with prostate cancer compared with usual care.

View Article and Find Full Text PDF

Background: High-intensity interval training and breathing exercises alone have well-documented health benefits in people with hypertension. This study aimed to investigated the effects of combining the two methods on physical health among adults with hypertension.

Methods: Ninety-six adults (59.

View Article and Find Full Text PDF

Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, was effective and well tolerated at a dose of 6 mg once daily through 1 year (52 weeks) in patients with moderate to severe plaque psoriasis in the phase 3 POETYK PSO-1 and POETYK PSO-4 trials. Patients completing PSO-1 or PSO-4 could enter the ongoing POETYK long-term extension trial and receive open-label deucravacitinib. Safety and efficacy were evaluated through 3 years (148 weeks; data cutoff date: June 15, 2022) in Japanese patients in these trials.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!